Trulicity® (dulaglutide) and nausea

How three regulators count nausea

The US label lists adverse reactions reported by at least 5% of adults on Trulicity® and more often than on placebo. Its main pool covers 1,670 adults treated for an average of 23.8 weeks, and section 14.1 notes that these people started on 0.75 mg or 1.5 mg and stayed there, with no step-up. ^[1] The Canadian monograph reuses the same placebo-controlled studies but tallies every event that emerged during treatment, whether or not the medicine caused it, and adds a pool of studies lasting up to 104 weeks. ^[4] The EU summary turns the trial data into frequency classes. ^[3]

Two numbers for the same 1.5 mg dose

The 1.5 mg dose appears at 21.1% in the placebo pool and at 13.4% in the dose trial. ^[1] The dose trial raised everyone from 0.75 mg in 4-week steps, while the earlier studies began at the final dose, so it is tempting to credit the step-up for the lower figure. The label does not draw that conclusion: the trials also differed in length, background medicines and population, and section 6.1 warns that rates from separate trials cannot be compared directly. ^[1]

What the label does say is that the adult schedule starts at 0.75 mg and rises in steps of at least 4 weeks to lower the risk of stomach and bowel reactions (section 2.1). ^[1] A 2024 modelling study built on the dose trial’s 1,842 participants reached a consistent view: in its simulations, nausea and vomiting were dose dependent and eased with repeated weekly doses, and the authors judged a minimum of 4 weeks on each dose before the next step to be appropriate, matching the labelled schedule. ^[6] It is a model rather than a new trial, and it does not replace the plan your prescriber sets.

When nausea peaks and when it settles

The US label gives no week of onset or typical duration; it reports how many people had nausea at least once. ^[1] The other two regulators go further. The EU summary says stomach and bowel events over up to 104 weeks were mostly mild or moderate, peaked in the first 2 weeks, fell quickly over the following 4 weeks and then stayed fairly level. ^[3] The Canadian monograph adds that the share of people with nausea at any one time settled by about 6 to 8 weeks, to roughly 3% on 0.75 mg and 6% on 1.5 mg. ^[4]

Dose increases follow a similar curve. In the 52-week study of 1.5 mg, 3 mg and 4.5 mg, the prevalence of nausea rose in every group during the first 8 weeks, while doses were still climbing, and declined once people reached their assigned dose. ^[4] The post hoc analysis of that trial found that people who had a stomach or bowel event were most likely to have it within 2 weeks of starting, and few had a new one after moving up to 3 mg or 4.5 mg. Several of its authors were affiliated with Eli Lilly, and a post hoc analysis can describe patterns but was not the question the trial was designed to answer. ^[5]

Severity, stopping and the long run

Nausea is the largest part of a wider group of stomach and bowel reactions, reported in the placebo pool by 21% on placebo, 32% on 0.75 mg and 41% on 1.5 mg. Investigators graded those on Trulicity® mild in 58% and 48% of cases, moderate in 35% and 42%, and severe in 7% and 11%. ^[1] Section 5.6 puts severe stomach and bowel reactions at 2.2% and 4.3% on the two doses, against 1.4% on placebo, and the label does not recommend Trulicity® for people with severe gastroparesis. ^[1]

Few people stopped because of nausea itself: 1.0% on 0.75 mg and 1.9% on 1.5 mg across all studies, mostly within the first 4 to 6 weeks, and 1.3% to 1.5% across the higher-dose groups. ^[3][4] REWIND, which followed 9,901 adults for a median of 5.4 years, reported a digestive adverse event in 47.4% on dulaglutide 1.5 mg and 34.1% on placebo, and nausea was the most frequent treatment-emergent event on dulaglutide, at 14.9%. ^[4][9]

What wider research adds

A systematic analysis of 32 phase 3 trials of GLP-1 receptor agonists found that the risk of nausea rose with dose across the class, and that people already taking metformin reported more nausea and vomiting. With liraglutide as the reference, dulaglutide carried a similar risk. Because it pooled published trial reports, it cannot correct for differences in how each trial collected side effects. ^[7]

The AWARD-6 trial, an open-label comparison funded by Eli Lilly, randomised 599 adults on metformin to weekly dulaglutide 1.5 mg or daily liraglutide 1.8 mg for 26 weeks. Nausea was reported by 20% and 18%, and 6% in each group stopped because of adverse events. ^[8] One trial in one population is a narrow base for ranking two medicines, and your prescriber weighs far more than nausea when choosing between them.

Why dulaglutide can unsettle the stomach

• What the label supports: dulaglutide slows how fast the stomach empties (section 12.1). That delay is dose dependent, largest after the first dose, smaller with each later dose and softened by a gradual increase (section 12.2). ^[1] The EU leaflet describes fullness, nausea or vomiting from delayed stomach emptying, occasionally severe. ^[3] This fits the early peak and later fading described above.
• Proposed but not measured for Trulicity®: nausea also travels through the nervous system. Cleveland Clinic explains that part of the brainstem watches the blood for signs of toxins and can set off nausea, and that nerves around the gut can do the same. ^[13] The Trulicity® documents do not measure whether dulaglutide acts through these routes in people.
• General medical background: MedlinePlus names slow stomach emptying, and medicines in the “glutide” family, among common causes of nausea, and notes that nausea can lead to unhealthy weight loss because it takes away the wish to eat. ^[11][12]

Other reasons you might feel sick

Starting a new medicine makes it easy to blame everything on the pen. MedlinePlus lists stomach flu, food poisoning, reflux, migraine, motion sickness, pregnancy, severe pain such as kidney stones and heavy cannabis use among common causes, and appendicitis, a blocked bowel and stomach ulcers among more serious ones. ^[11] Cleveland Clinic adds that strong emotions, smells and even memories can bring on nausea by themselves. ^[13]

Two causes deserve a word because of Trulicity® itself. If there is any chance of pregnancy, tell your doctor: the EU leaflet says Trulicity® should not be used during pregnancy. ^[3] And metformin, which everyone in the higher-dose trial was taking, was linked to more nausea in the analysis above. ^[1][7]

Easing nausea, according to the sources

A 2025 review for primary care doctors says that managing the stomach side effects of these medicines should start with diet: smaller, more frequent meals, enough fluids, and avoiding foods high in fat or sugar. If symptoms continue, prescribers can try medicines for relief. ^[10] MedlinePlus suggests sitting quietly when you feel queasy, sipping clear liquids through the day, choosing bland foods and foods with plenty of water in them, staying upright after eating, and eating somewhere calm and free of strong smells. It advises steering clear of greasy, very salty, spicy or strongly scented food, and of caffeine, alcohol and fizzy drinks. ^[12]

Cleveland Clinic adds a few practical points: eat and drink more slowly, avoid food served very hot if heat sets you off, give yourself time after a meal before exertion, and wait a while before brushing your teeth after eating. It notes that over-the-counter anti-nausea medicines exist but are best checked with a pharmacist or provider first. ^[13] The Trulicity® Medication Guide asks you to keep drinking fluids and to let your provider know promptly if nausea, vomiting or diarrhoea keeps going. ^[2]

Trulicity® is a registered trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.